

Resource Summary Report

Generated by [NIF](#) on Sep 23, 2026

OCI-Ly18

RRID:CVCL_1880

Type: Cell Line

Proper Citation

RRID:CVCL_1880

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1880

Proper Citation: RRID:CVCL_1880

Description: Cell line OCI-Ly18 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma

Defining Citation: [PMID:1311715](#), [PMID:8574164](#), [PMID:11807979](#), [PMID:19278952](#), [PMID:20628145](#), [PMID:26727417](#)

Comments: From: Ontario Cancer Institute (OCI); Toronto; Canada., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-Ly18

Synonyms: OCI-LY18, OCI-LY-18, OCILY18, OCI-Ly 18, Ly18, LY18

Cross References: BioSample:SAMN03473448, cancercellines:CVCL_1880, ChEMBL-Cells:ChEMBL4523522, ChEMBL-Targets:ChEMBL4523553, Cosmic:1295513, Cosmic:1517651, Cosmic:1541906, Cosmic:1636683, Cosmic:2276334, DepMap:ACH-001616, DSMZ:ACC-699, DSMZCellDive:ACC-699, GEO:GSM380131, GEO:GSM552456, GEO:GSM1374785, Progenetix:CVCL_1880, PubChem_Cell_line:CVCL_1880, Wikidata:Q54931770

ID: CVCL_1880

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260920T005334+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly18.

No alerts have been found for OCI-Ly18.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. Cancer research communications, 6(7), 1619.

Liu S, et al. (2026) ?-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. Cell, 189(6), 1701.

Wang L, et al. (2026) A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. Journal of hematology & oncology, 19(1).

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Porazzi P, et al. (2025) EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer cell, 43(3), 537.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 54(1), 116.